Sign up to save your podcasts
Or
Share The Underdog Brand That Went from Zero to $1M in 10 Months
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Underdog Brand That Went from Zero to $1M in 10 Months
While health-conscious consumers scrutinize ingredients in their protein powder, they're still taking bright pink liquid for upset stomachs without a second thought. Hilma bridged this disconnect—and went from launch to acquisition by a French pharmaceutical giant in just four years, scaling to over 10,000 retail doors.
The founders spotted the gap in 2017: clean-label values had transformed food and beauty, but medicine cabinets remained full of synthetic dyes and preservatives. They launched in January 2020 with a radical thesis—treat natural remedies like pharmaceutical companies treat drugs, conducting clinical studies with 70+ participants per product to create an entirely new category they called "Clinical Herbals".
What made this strategic compression possible:
- IRB-approved clinical trials on every product, converting skepticism into measurable efficacy data (94% experienced decreased upset stomach within 30 minutes)
- OTC aisle placement at Target instead of the supplement section, positioning products as medicine for immediate relief rather than daily wellness supplements
- Depth over breadth: launched 3 clinically validated products instead of 20 unproven SKUs, with 73% focus on digestive health until category leadership was established
- Omnichannel from day one: $1M in DTC sales in 10 months proved concept, then scaled retail methodically (750 Target stores to 10,000 doors by acquisition)
- Pandemic timing amplified macro trends around immunity and clean ingredients, compressing a decade of consumer behavior shift into months
Clinical validation became both moat and marketing. Competitors can't easily replicate millions in research investment, IRB approvals, and registered trials on clinicaltrials.gov. This evidence-based approach removed the primary barrier to natural remedies adoption—customers didn't believe they worked. The data made believers out of skeptics and turned Walmart into an inbound suitor specifically seeking Hilma for their digestive health assortment.
When trust is the bottleneck to category adoption, proof is worth more than any ad campaign. Hilma chose expensive, slow clinical validation over fast product launches—a hard choice that built category authority instead of commodity positioning. The result: Biocodex Group acquired them in November 2022, gaining access to digitally native customers and the US natural remedies market while Hilma gained pharmaceutical R&D resources and distribution across 120+ countries.
View all episodes
By Cody SchneiderWhile health-conscious consumers scrutinize ingredients in their protein powder, they're still taking bright pink liquid for upset stomachs without a second thought. Hilma bridged this disconnect—and went from launch to acquisition by a French pharmaceutical giant in just four years, scaling to over 10,000 retail doors.
The founders spotted the gap in 2017: clean-label values had transformed food and beauty, but medicine cabinets remained full of synthetic dyes and preservatives. They launched in January 2020 with a radical thesis—treat natural remedies like pharmaceutical companies treat drugs, conducting clinical studies with 70+ participants per product to create an entirely new category they called "Clinical Herbals".
What made this strategic compression possible:
- IRB-approved clinical trials on every product, converting skepticism into measurable efficacy data (94% experienced decreased upset stomach within 30 minutes)
- OTC aisle placement at Target instead of the supplement section, positioning products as medicine for immediate relief rather than daily wellness supplements
- Depth over breadth: launched 3 clinically validated products instead of 20 unproven SKUs, with 73% focus on digestive health until category leadership was established
- Omnichannel from day one: $1M in DTC sales in 10 months proved concept, then scaled retail methodically (750 Target stores to 10,000 doors by acquisition)
- Pandemic timing amplified macro trends around immunity and clean ingredients, compressing a decade of consumer behavior shift into months
Clinical validation became both moat and marketing. Competitors can't easily replicate millions in research investment, IRB approvals, and registered trials on clinicaltrials.gov. This evidence-based approach removed the primary barrier to natural remedies adoption—customers didn't believe they worked. The data made believers out of skeptics and turned Walmart into an inbound suitor specifically seeking Hilma for their digestive health assortment.
When trust is the bottleneck to category adoption, proof is worth more than any ad campaign. Hilma chose expensive, slow clinical validation over fast product launches—a hard choice that built category authority instead of commodity positioning. The result: Biocodex Group acquired them in November 2022, gaining access to digitally native customers and the US natural remedies market while Hilma gained pharmaceutical R&D resources and distribution across 120+ countries.